Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166


SUMOylation Regulates Transcription by the Progesterone Receptor A Isoform in a Target Gene Selective Manner.

Abdel-Hafiz HA, Dudevoir ML, Perez D, Abdel-Hafiz M, Horwitz KB.

Diseases. 2018 Jan 2;6(1). pii: E5. doi: 10.3390/diseases6010005.


Role of epigenetic modifications in luminal breast cancer.

Abdel-Hafiz HA, Horwitz KB.

Epigenomics. 2015 Aug;7(5):847-62. doi: 10.2217/epi.15.10. Epub 2015 Feb 17. Review.


Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.

Ogba N, Manning NG, Bliesner BS, Ambler SK, Haughian JM, Pinto MP, Jedlicka P, Joensuu K, Heikkilä P, Horwitz KB.

Breast Cancer Res. 2014 Dec 5;16(6):489. doi: 10.1186/s13058-014-0489-4.


Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling.

Pinto MP, Dye WW, Jacobsen BM, Horwitz KB.

BMC Cancer. 2014 Oct 1;14:735. doi: 10.1186/1471-2407-14-735.


Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.

Knox AJ, Scaling AL, Pinto MP, Bliesner BS, Haughian JM, Abdel-Hafiz HA, Horwitz KB.

Breast Cancer Res. 2014 Aug 13;16(4):418. doi: 10.1186/s13058-014-0418-6.


Post-translational modifications of the progesterone receptors.

Abdel-Hafiz HA, Horwitz KB.

J Steroid Biochem Mol Biol. 2014 Mar;140:80-9. doi: 10.1016/j.jsbmb.2013.12.008. Epub 2013 Dec 12. Review.


ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases.

Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkilä P.

Breast Cancer (Auckl). 2013;7:23-34. doi: 10.4137/BCBCR.S10701. Epub 2013 Feb 13.


Genomic signatures of pregnancy-associated breast cancer epithelia and stroma and their regulation by estrogens and progesterone.

Harvell DM, Kim J, O'Brien J, Tan AC, Borges VF, Schedin P, Jacobsen BM, Horwitz KB.

Horm Cancer. 2013 Jun;4(3):140-53. doi: 10.1007/s12672-013-0136-z. Epub 2013 Mar 12.


Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features.

Jambal P, Badtke MM, Harrell JC, Borges VF, Post MD, Sollender GE, Spillman MA, Horwitz KB, Jacobsen BM.

Breast Cancer Res Treat. 2013 Jan;137(2):431-48. doi: 10.1007/s10549-012-2377-x. Epub 2012 Dec 18.


Control of progesterone receptor transcriptional synergy by SUMOylation and deSUMOylation.

Abdel-Hafiz HA, Horwitz KB.

BMC Mol Biol. 2012 Mar 22;13:10. doi: 10.1186/1471-2199-13-10.


Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch.

Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW, Sartorius CA, Tan AC, Heikkilä P, Perou CM, Horwitz KB.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2742-7. doi: 10.1073/pnas.1106509108. Epub 2011 Oct 3.


Progesterone receptors, their isoforms and progesterone regulated transcription.

Jacobsen BM, Horwitz KB.

Mol Cell Endocrinol. 2012 Jun 24;357(1-2):18-29. doi: 10.1016/j.mce.2011.09.016. Epub 2011 Sep 17. Review.


Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint.

Badtke MM, Jambal P, Dye WW, Spillman MA, Post MD, Horwitz KB, Jacobsen BM.

Breast Cancer Res Treat. 2012 Jan;131(1):75-87. doi: 10.1007/s10549-011-1399-0. Epub 2011 Feb 22.


An immunohistochemical method to study breast cancer cell subpopulations and their growth regulation by hormones in three-dimensional cultures.

Pinto MP, Jacobsen BM, Horwitz KB.

Front Endocrinol (Lausanne). 2011 Jun 21;2:15. doi: 10.3389/fendo.2011.00015. eCollection 2011.


Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis.

Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, Jacobsen BM, Horwitz KB.

Cancer Res. 2010 Nov 1;70(21):8927-36. doi: 10.1158/0008-5472.CAN-10-1238. Epub 2010 Oct 19.


Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.

Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA.

Breast Cancer Res Treat. 2011 Jul;128(1):45-55. doi: 10.1007/s10549-010-1078-6. Epub 2010 Jul 28.


Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer.

Pinto MP, Badtke MM, Dudevoir ML, Harrell JC, Jacobsen BM, Horwitz KB.

Cancer Res. 2010 Apr 1;70(7):2655-64. doi: 10.1158/0008-5472.CAN-09-4373. Epub 2010 Mar 23.


The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling.

Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Barón AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL.

J Clin Invest. 2009 Sep;119(9):2678-90. doi: 10.1172/JCI37815. Epub 2009 Aug 24.


ALU repeats in promoters are position-dependent co-response elements (coRE) that enhance or repress transcription by dimeric and monomeric progesterone receptors.

Jacobsen BM, Jambal P, Schittone SA, Horwitz KB.

Mol Endocrinol. 2009 Jul;23(7):989-1000. doi: 10.1210/me.2009-0048. Epub 2009 Apr 16.


Mechanisms underlying the control of progesterone receptor transcriptional activity by SUMOylation.

Abdel-Hafiz H, Dudevoir ML, Horwitz KB.

J Biol Chem. 2009 Apr 3;284(14):9099-108. doi: 10.1074/jbc.M805226200. Epub 2009 Feb 11.


Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis.

Horwitz KB, Sartorius CA.

J Clin Endocrinol Metab. 2008 Sep;93(9):3295-8. doi: 10.1210/jc.2008-0938. Epub 2008 Jul 22.


Progesterone receptor action: translating studies in breast cancer models to clinical insights.

Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, Horwitz KB, Jacobsen BM.

Adv Exp Med Biol. 2008;630:94-111. Review.


ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease.

Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus RR, Richer JK.

Mod Pathol. 2008 Jul;21(7):912-23. doi: 10.1038/modpathol.2008.82. Epub 2008 May 16.


Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.

Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA.

Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5774-9. doi: 10.1073/pnas.0706216105. Epub 2008 Apr 7.


Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor.

Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VF, Elias AD, Horwitz KB.

Breast Cancer Res Treat. 2008 Dec;112(3):489-501. doi: 10.1007/s10549-008-9923-6. Epub 2008 Mar 13.


Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance.

Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK.

Breast Cancer Res Treat. 2008 Dec;112(3):475-88. doi: 10.1007/s10549-008-9897-4. Epub 2008 Mar 9.


Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis.

Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA, Horwitz KB.

Cancer Res. 2007 Nov 1;67(21):10582-91.


Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone.

Jones MC, Fusi L, Higham JH, Abdel-Hafiz H, Horwitz KB, Lam EW, Brosens JJ.

Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16272-7. Epub 2006 Oct 19.


Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.

Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D.

Br J Cancer. 2006 Nov 6;95(9):1220-8. Epub 2006 Oct 17.


Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes.

Harrell JC, Dye WW, Allred DC, Jedlicka P, Spoelstra NS, Sartorius CA, Horwitz KB.

Cancer Res. 2006 Sep 15;66(18):9308-15.


Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium.

Jacobsen BM, Harrell JC, Jedlicka P, Borges VF, Varella-Garcia M, Horwitz KB.

Cancer Res. 2006 Aug 15;66(16):8274-9.


Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B.

Tung L, Abdel-Hafiz H, Shen T, Harvell DM, Nitao LK, Richer JK, Sartorius CA, Takimoto GS, Horwitz KB.

Mol Endocrinol. 2006 Nov;20(11):2656-70. Epub 2006 Jun 8.


The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers.

Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh M, Shroyer KR, Broaddus RR, Horwitz KB, Richer JK.

Cancer Res. 2006 Apr 1;66(7):3893-902.


GCUNC-45 is a novel regulator for the progesterone receptor/hsp90 chaperoning pathway.

Chadli A, Graham JD, Abel MG, Jackson TA, Gordon DF, Wood WM, Felts SJ, Horwitz KB, Toft D.

Mol Cell Biol. 2006 Mar;26(5):1722-30.


Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth.

Sartorius CA, Harvell DM, Shen T, Horwitz KB.

Cancer Res. 2005 Nov 1;65(21):9779-88.


Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture.

Harvell DM, Richer JK, Allred DC, Sartorius CA, Horwitz KB.

Endocrinology. 2006 Feb;147(2):700-13. Epub 2005 Oct 20.


Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75.

Carvajal A, Espinoza N, Kato S, Pinto M, Sadarangani A, Monso C, Aranda E, Villalon M, Richer JK, Horwitz KB, Brosens JJ, Owen GI.

Breast Cancer Res Treat. 2005 Nov;94(2):171-83.


Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells.

Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR.

J Steroid Biochem Mol Biol. 2005 Dec;97(4):328-41. Epub 2005 Sep 12.


Insights into the role of progesterone receptors in breast cancer.

Fuqua SA, Cui Y, Lee AV, Osborne CK, Horwitz KB.

J Clin Oncol. 2005 Feb 1;23(4):931-2; author reply 932-3. No abstract available.


Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1.

Kato S, Pinto M, Carvajal A, Espinoza N, Monso C, Sadarangani A, Villalon M, Brosens JJ, White JO, Richer JK, Horwitz KB, Owen GI.

J Clin Endocrinol Metab. 2005 Feb;90(2):1181-8. Epub 2004 Nov 23.


Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates.

Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SA.

Clin Cancer Res. 2004 Apr 15;10(8):2751-60.


Expression profiling of human breast cancers and gene regulation by progesterone receptors.

Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB.

J Mammary Gland Biol Neoplasia. 2003 Jul;8(3):257-68. Review.


Functional properties of the N-terminal region of progesterone receptors and their mechanistic relationship to structure.

Takimoto GS, Tung L, Abdel-Hafiz H, Abel MG, Sartorius CA, Richer JK, Jacobsen BM, Bain DL, Horwitz KB.

J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):209-19.


Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts.

Sartorius CA, Shen T, Horwitz KB.

Breast Cancer Res Treat. 2003 Jun;79(3):287-99.


Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors.

Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA.

Mol Endocrinol. 2003 Apr;17(4):628-42. Epub 2003 Jan 9.


Supplemental Content

Loading ...
Support Center